Single-centre, non-randomised clinical trial at a tertiary care centre to investigate 1-year changes in social experiences and biomarkers of well-being after bariatric surgery in individuals with severe obesity: protocol for the Bariatric Surgery and Social Experiences (BaSES) study

Daniela Melitta Pfabigan,1,2,3 Jens Kristoffer Hertel,2 Marius Svanevik,2,4 Morten Lindberg,5 Uta Sailer1, Jøran Hjelmesæth2,6

ABSTRACT

Introduction Obesity is linked to increased loneliness and less enjoyment of social interactions. While bariatric surgery is the most effective treatment targeting severe obesity, there is limited understanding as to whether patients experience social interactions differently after surgery. The Bariatric Surgery and Social Experiences study is designed to assess potential changes in how much patients enjoy and engage in daily social interactions 1 year after Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG).

Methods and analysis Single-centre, non-randomised clinical trial carried out at the Department of Endocrinology, Obesity and Nutrition at Vestfold Hospital Trust, Norway. Eligible patients (N=113) will undergo either RYGB, SG or single anastomosis sleeve ileal (SASI) bypass. The primary outcome measure is change in the social experience score (assessed with a questionnaire) from a presurgery to a follow-up assessment 1 year after RYGB and SG. The respective changes after SASI bypass will be assessed and considered exploratory.

Ethics and dissemination The most recent protocol version of this study was reviewed and approved by the Regional Committee for Medical Research Ethics South East Norway (REK sør-øst A) on 29 August 2022 (ref: 238406). The results will be disseminated to academic and health professional audiences and the public via publications in international peer-reviewed journals and conferences.

Trial registration number NCT05207917.

INTRODUCTION

Obesity is one of the world's most serious public health problems as defined by the WHO. Currently, the most effective treatment at achieving lasting weight loss and long-term reduction in obesity-related comorbidities is bariatric surgery.1 2 The two most commonly performed procedures are sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB),3 but more recently a combination of both (single anastomosis sleeve ileal (SASI) bypass) has been introduced.4

The effectiveness of bariatric surgery has most often been measured as weight loss and reductions in obesity-related comorbidities and/or comorbidities, while effects on social interaction and subjective experience have received much less attention (see Broadhead et al, Uchino and Rubino et al5–7). This appears to be an important omission as there is ample evidence that (supportive) social relationships promote health8 and decrease...
mortality risk. Social relationships can affect a range of other health conditions such as cardiovascular disease, cancer and immune function. However, individuals with obesity may experience social interactions as less positive than normal-weight individuals. Studies have reported that individuals with obesity avoid social events and relationships, but also career opportunities, shopping and other activities where they might feel observed because of weight stigma. Such avoidance behaviour can lead to a ‘chronic disengagement’ of diverse aspects of social life, which in turn might decrease interpersonal skills. Further investigations into the link between social behaviour and eating found that greater emotional eating was associated with greater social avoidance. Eating was described as a means to cope with loneliness on the one hand, while on the other hand aggravating feelings of being alone due to the stigma associated with obesity. As such, loneliness and obesity can create a vicious circle. Similarly, individuals with severe obesity reported deriving less enjoyment from social contacts and often feel more socially isolated than normal-weight individuals.

Only a few studies have investigated how bariatric surgery influences social interactions. One 10 year follow-up study found improvements in social interactions for bariatric surgery, but not for conventional weight loss treatment. A retrospective study observed a positive association between weight loss after bariatric surgery and the participants’ social connections. In qualitative studies, many participants reported that they received more positive social feedback following bariatric surgery, and also that they enjoyed social activities more than before, while others have described ambiguous feelings, or even negative psychosocial experiences.

The current clinical trial will address this important knowledge gap and investigate the effects of the two most common bariatric surgery procedures (RYGB and SG) on patients’ subjective experience of daily social interactions 1 year after surgery. Additionally, biological and psychological markers of social experiences will be assessed in this trial.

Objectives

Primary objectives
The primary objective of this study is to determine 1 year changes in patients’ subjective experience of daily social interactions after bariatric surgery (either RYGB or SG).

Secondary objectives
Key secondary objectives are the examination of changes in variables assessing broader aspects of social experiences as secondary endpoints (affect and reactivity to social inclusion and exclusion, response to pleasant caress-like touch and one’s preferred velocity for self-applied caress-like touch) and biomarkers of well-being (cortisol and endocannabinoid concentrations from hair samples). Moreover, we will explore whether the primary and secondary endpoints also change in a short-term follow-up (6 weeks after surgery; T1) and whether RYGB leads to larger changes in social interactions and in secondary endpoints related to social experiences than SG. In addition, we will explore changes in psychological (reward responsivity, social network and belonging, body image and interoceptive ability, self-reported eating behaviour) and health-related (obesity-related quality of life, psychological distress) patient-reported outcomes (PROs), changes in gut hormones (ghrelin) and changes in anthropometric measures, body composition and cardiovascular risk factors in the surgery groups 6 weeks (T1) and 1 year (T2) after surgery. All outcomes will be considered exploratory.

Trial design
This study is a single-centre, non-randomised clinical trial with two experimental groups (RYGB, SG). A third exploratory group will constitute of patients undergoing SASI bypass.

METHODS AND ANALYSIS
This protocol follows the SPIRIT reporting guidelines.

Study setting
The study is conducted at a tertiary healthcare centre, the Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust (Norway). Before the COVID-19 pandemic, about 180–200 bariatric surgeries were performed per year (about 65% RYGB and 35% SG). During the pandemic, the number of bariatric surgeries decreased to about 120 per year (with a similar distribution of the two surgery types as before the pandemic). The SASI bypass procedure was first implemented in 2022.

Patient and public involvement
A patient representative serves on the study steering committee to ensure that patients’ interests and opinions are taken into consideration during all study phases. The patients will be informed about published findings during the study period.

Eligibility criteria

Inclusion criteria
1. Eligibility for one of the surgery types
2. Scheduled surgery
3. Willingness and ability to give informed consent for study participation
4. Aged between 18 and 80 years
5. Good understanding of written and spoken Norwegian in order to answer the PRO-related questionnaires

Exclusion criteria
1. Pregnancy and breast feeding
2. Severe chronic diseases such as endocrine, heart, neurological, lung, gastrointestinal or kidney conditions
3. Cancer
4. Acute psychotic episode

SASI bypass procedure was first implemented in 2022.
Experimental groups

The current trial is not an intervention study. All participants will undergo one type of bariatric surgery and will thus be assigned to an experimental group, but this assignment will not directly influence study outcomes. The study outcome variables will only be observed before and after each surgery type. All surgical procedures will be performed laparoscopically by experienced surgical teams at Vestfold Hospital Trust.

Experimental group 1: RYGB

In RYGB, the left crus will be dissected free and significant hiatal hernias repaired with posterior cruralplasty. The minor curvature will be opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler using the full length of the stapler, creating an antecolic, antegastric alimentary limb. The opening will then be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. Finally, the small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.

Experimental group 2: SG

In SG, a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 1–2 cm from the pylorus up to the angle of Hiss. The left crus is then visualised and inspected for hiatal hernia. Clinically significant hiatal hernias will be repaired with posterior cruralplasty. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always purple, while tan loads are used for the rest of the ventricle. The last stapler is placed 5–10 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis; no oversewing or buttressing material is routinely used.

Experimental group 3: SASI bypass

The SG is performed as described above, with the exception that the division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300 cm from the ileocecal valve, in sequences of 5 cm, with the small bowel stretched and markers placed on the graspers. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori and connected to the small bowel with a 30 mm stapled anastomosis completed with an absorbable running suture. The mesenteric defect is not closed.

Concomitant care

Patients will follow standard treatment procedures at the Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust. There are no specific concomitant care or interventions that are permitted or prohibited during the trial.

Outcome measures

Primary outcome measure

Change in social experience score (PRO: The Social Experiences’ Daily Occurrence (SOLO) Scale) from 4 weeks before surgery to 1 year after surgery. The SOLO is a short questionnaire assessing occurrence and quality of participants’ daily social interactions (both meaningful and superficial) in the 14 days following each visit.

Secondary outcome measures

Secondary outcome measures are listed in box 1, and are assessed as summary measures such as mean/median or proportions (when appropriate) for each group. Outcome variables constitute the assessed values/scores per measurement time point and changes from baseline (Baseline: 4 weeks prior to surgery) to the short-term follow-up (T1: 6 weeks after surgery) and to the long-term follow-up (T2: 1 year after surgery); see table 1.

Participant timeline

The Bariatric Surgery and Social Experiences (BaSES) study includes four time points where the patients are invited to the Department of Endocrinology, Obesity

Box 1 Secondary outcome measures

<table>
<thead>
<tr>
<th>Social experience facets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion/exclusion experience</td>
<td></td>
</tr>
<tr>
<td>Preferred velocity of self-applied touch</td>
<td></td>
</tr>
<tr>
<td>Pleasance of self-applied touch</td>
<td></td>
</tr>
<tr>
<td>Pleasance of other-applied touch</td>
<td></td>
</tr>
<tr>
<td>Biomarkers of well-being</td>
<td></td>
</tr>
<tr>
<td>Hair cortisol concentration</td>
<td></td>
</tr>
<tr>
<td>Endocannabinoid concentration</td>
<td></td>
</tr>
<tr>
<td>Psychological patient-reported outcomes</td>
<td></td>
</tr>
<tr>
<td>Reward responsibility</td>
<td></td>
</tr>
<tr>
<td>Social network and belonging</td>
<td></td>
</tr>
<tr>
<td>Body image and interoceptive ability</td>
<td></td>
</tr>
<tr>
<td>Self-reported eating behaviour</td>
<td></td>
</tr>
<tr>
<td>Gut hormones</td>
<td></td>
</tr>
<tr>
<td>Fasting ghrelin concentrations</td>
<td></td>
</tr>
<tr>
<td>Health-related patient-reported outcomes</td>
<td></td>
</tr>
<tr>
<td>Health-related quality of life</td>
<td></td>
</tr>
<tr>
<td>Obesity-related quality of life</td>
<td></td>
</tr>
<tr>
<td>Psychological distress</td>
<td></td>
</tr>
<tr>
<td>Body weight and composition</td>
<td></td>
</tr>
<tr>
<td>Body weight, body mass index, waist and hip circumference</td>
<td></td>
</tr>
<tr>
<td>Body composition</td>
<td></td>
</tr>
<tr>
<td>Standard blood tests and cardiovascular risk factors</td>
<td></td>
</tr>
<tr>
<td>Resting systolic and diastolic blood pressure</td>
<td></td>
</tr>
<tr>
<td>Cholesterol and triglyceride levels</td>
<td></td>
</tr>
<tr>
<td>Glucose metabolites</td>
<td></td>
</tr>
</tbody>
</table>

and Nutrition. Study enrolment started in May 2022 with screening meetings. The baseline assessment takes place approximately 4 weeks before surgery, the short-term follow-up is scheduled approximately 6 weeks after surgery (T1) and the long-term follow-up is scheduled approximately 1 year after surgery (T2). Up until the end of 2022, 26 patients underwent the baseline assessments. It is expected that the long-term follow-up (T2) will be finished in 2025 (Table 1).

**Table 1** Patient visit schedule

<table>
<thead>
<tr>
<th>Visit</th>
<th>Screening/information meeting</th>
<th>Baseline (~4 weeks prior to surgery)</th>
<th>T1 follow-up (~6 weeks after surgery)</th>
<th>T2 follow-up (~1 year after surgery)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Signed informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRO: SOLO</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychological and health-related PROs</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social experience tasks</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular medication</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hair samples</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood samples</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body composition</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthropometric measures</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PROs, patient-reported outcomes; SOLO, The SOcial Experiences’ DaiLy Occurrence Scale.

Study inclusion will be assessed according to inclusion and exclusion criteria during this meeting. Patients who approve participation and pass eligibility criteria will then sign the informed consent form and will be enrolled in the study.

**Allocation: sequence generation and concealment**

Participants will be numbered sequentially based on enrolment. No concealment regarding surgery type is implemented.

**Blinding**

Due to the nature of the non-randomised controlled trial, neither participants nor staff will be blinded to the surgery type.

**Data collection methods**

**Primary outcome**

Changes in the social experience score: after each BaSES study visit, participants are asked to fill in the SOLO Scale in the 14 days following their visit. The SOLO is a 14-item questionnaire assessing occurrence and quality of one’s daily social interactions. The questionnaire is supposed to be filled in at the end of the day, taking between 2 and 5 min. It is available either in an online version or on paper. Participants will receive individual reminders each day in order to enhance compliance. A total item score will be calculated over the 14 assessment days at the three visits (Baseline, T1, T2). A change in the total SOLO score from baseline to the long-term follow-up (T2), irrespective of surgery type, constitutes the primary outcome.

**Secondary and exploratory outcomes**

See online supplemental materials for a detailed description of the measurement of affect and reactivity to social inclusion and exclusion, and of subjective experience of
caress-like other-applied and self-applied touch. Cortisol and endocannabinoid concentrations will be measured from hair samples and analysed by Dresden LabService GmBH (Dresden, Germany). The full list of the administered psychological and health-related questionnaires and a detailed description of the assessed anthropometric measures is provided in online supplemental materials. Routine laboratory measurements will be performed at the Central Laboratory, Vestfold Hospital Trust, while C-peptide analyses will be performed at the Hormone Laboratory, Oslo University Hospital. Both laboratories are certified according to NO-EN ISO 15189. A detailed list of method principles, sample matrix, units and analytical precision of biological outcomes are provided in online supplemental table S1.

Retention
Participants may withdraw from the study for any reason at any time but may also be excluded by study personnel in order to protect their safety and/or if they are unable/unwilling to comply with the study procedures. However, reasonable effort is made by the study personnel to prevent attrition throughout the study period. Loss to follow-up measurement sessions of the primary outcome is estimated to be ≤35%.

Data management
Trained study personnel will enter all data into online case report forms (CRFs) during the study visits. CRFs will be saved on an encrypted server that requires two-factor authentication of authorised personal (TSD—Service for Sensitive Data, University of Oslo). SOLO data are directly transferred and saved on this server. The log files from the tasks assessing experience of social inclusion/exclusion and touch will be manually transferred to this server. Data integrity is continuously monitored by members of the steering committee.

Data will be stored in a pseudoanonymised way because study-generated participant codes will be used. Participants’ data will be stored for a period of at least 5 years after completion of the study.

Statistical methods
Descriptive data will be presented as mean (SD), median (range) or number (percentage). Within-group comparisons of differences between baseline and T2 (primary objective), and baseline and T1 will be calculated with dependent t-tests or non-parametric alternatives. Between-group comparisons of differences between RYGB and SG (and SASI bypass in an explorative manner) will be calculated with independent t-tests, one-way analysis of variance (ANOVA) or non-parametric alternatives. Interactions between within-group and between-group comparisons will be analysed using either a multilevel modelling approach (where appropriate; also to handle missing data) or mixed ANOVAs. Correlation and regression approaches will be used for the exploration of mediating or independent effects of surgery type, hormone concentrations or PRO scores on the primary outcome and selected secondary outcomes.

Data monitoring
The steering committee consists of a team of healthcare professionals, researchers and a patient representative. Members of the steering committee meet every 12 months to safeguard the interests of patients participating in BaSES. It further monitors the progress and overall conduct of the clinical trial. Adverse events will be consecutively reported. The harms of the applied experimental assessments are extremely low and pose no risk for participants. Due to the low-risk nature of BaSES, the steering committee also assumes the role of the data monitoring committee.

Ethics and dissemination
Research ethics approval
The study protocol was registered in an international trial register (ClinicalTrials.gov). The study is conducted in accordance with Good Clinical Practice, International Council of Harmonization (ICH) guidelines and the latest revision of the Declaration of Helsinki.

Protocol amendments
Significant amendments to the protocol have been and will be made only after ethical approval by the regional ethics committee.

Informed consent
Individual informed consent was obtained in information/screening meetings consisting of either individual patients or small patient groups.

Ancillary studies
Additional blood samples will be obtained and stored for use in future studies. Information about storage and analyses of these samples is covered in the informed consent.

Confidentiality
Each participant is given a study ID that will be used during data collection and analysis. The key linking participants’ names and study ID are stored on a high-security server with two-factor authentication. No participant information will be released outside the study.

Access to data
Electronically authorised data access is available only to selected study personnel. Data analyses must either be performed according to the preplanned statistical analysis plan or should be authorised by the study principal investigators before they are carried out. Deanonymised individual participant data can be made available following publication on reasonable request to authors US and JH. Data will be shared according to the consent given by the participants and Norwegian laws and legislation.

Ancillary and post-trial care
All patients will receive post-trial follow-up care according to national guidelines.30
Dissemination

The protocol and the results of the study will be published in international peer-reviewed journals in accordance with the ICMJE criteria for authorship (http://www.icmje.org/). Furthermore, study findings will be disseminated via scientific networks, conferences, professionals, policymakers and commissioners of weight management.

Author affiliations
1Department of Behavioural Medicine, University of Oslo, Oslo, Norway
2Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway
3Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway
4Department of Gastrointestinal Surgery, Vestfold Hospital Trust, Tønsberg, Norway
5Department of Endocrinology, Morbid Obesity and Preventive Medicine, University of Oslo, Oslo, Norway

Author details
Daniela Melitta Pfabigan http://orcid.org/0000-0002-4043-1695
Jens Kristoffer Hertel http://orcid.org/0000-0002-8693-7018
Marius Svanek http://orcid.org/0000-0003-4303-5935
Morten Lindberg http://orcid.org/0000-0002-5568-7810
Uta Sailer http://orcid.org/0000-0002-9728-8738
Jaran Hjelmestad http://orcid.org/0000-0002-1995-0562

Twitter Daniela Melitta Pfabigan @DPfabigan and Uta Sailer @UtaSailer

Contributors
Original idea of the study was given by US and JH. US, DMP, JKH and JH designed the study. DMP helped in study implementation. MS and ML provided input to methods. Data curation was done by DMP. DMP wrote the first version of the manuscript. JH and US acquired funding. All authors contributed and agreed to the final version of the manuscript.

Funding
The first author received an educational grant from the South-Eastern Norway Regional Health Authority (grant number: 2021046). In addition, the recruitment, inclusion and follow-up of patients are organised and financed by the Vestfold Hospital Trust and the Department of Endocrinology, Obesity and Nutrition (grant number: N/A). All members of the study staff receive a salary from the study centre. These funding sources had no role in the study design nor in the decision to submit the paper for publication.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from reliance placed on the content. Where the content is a derivative work, BMJ does not warrant the accuracy, reliability or completeness of any part, nor accepts any responsibility for any error or omissions arising from translation and adaptation.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Daniela Melitta Pfabigan http://orcid.org/0000-0002-4043-1695
Jens Kristoffer Hertel http://orcid.org/0000-0002-8693-7018
Marius Svanek http://orcid.org/0000-0003-4303-5935
Morten Lindberg http://orcid.org/0000-0002-5568-7810
Uta Sailer http://orcid.org/0000-0002-9728-8738
Jaran Hjelmestad http://orcid.org/0000-0002-1995-0562

REFERENCES


Copyright BMJ Publishing Group Ltd. Group Ltd.